Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?

Clinical trial results Leadership change Product recall AI-generated analysis

🩺 Becton Dickinson's Revello Vascular Covered Stent met its primary endpoint in the AGILITY trial for iliac artery disease after nine months of data collection.

🀝 The company secured a new U.S. government manufacturing partnership during a busy October that also saw a leadership change in its Surgery unit.

πŸ“ˆ BDX shares have rallied 20.28% over the past 90 days, driven by momentum despite a year-to-date decline of 6.25%.

🏭 Over 90% of Becton Dickinson's revenue now comes from businesses growing in the mid-to-high single digits following its strategic portfolio focus.

πŸ’° Following the Waters separation, the company returned $3.1 billion to shareholders and retired $2.1 billion in debt while keeping net leverage at 2.9x.

πŸ“‰ Key platforms including biologic drug delivery, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration are growing at double-digit rates with higher gross margins.

⚠️ An active product recall underscores ongoing execution risks across Becton Dickinson's broader portfolio.

πŸ‡¨πŸ‡³ The company faces real pressure if weakness in the Chinese market persists or impacts its global operations.

βš–οΈ Analysts estimate a fair value of $195.67 for BDX, indicating the stock may still be undervalued despite recent gains.

πŸ”¬ Potential risks include expanded FDA actions or longer resolution times regarding infection prevention products.

Bullish Signals
  • Becton Dickinson's Revello Vascular Covered Stent successfully hit its primary endpoint in the AGILITY trial for iliac artery disease, validating the product's efficacy.
  • The company secured a new U.S. government manufacturing partnership, signaling strong demand and operational capacity.
  • BDX shares have gained 20.28% over the past 90 days, reflecting strong investor momentum and market confidence.
  • More than 90% of revenue comes from businesses growing in the mid-to-high single digits, providing a stable foundation for earnings growth.
  • Key platforms such as biologic drug delivery, Advanced Patient Monitoring, PureWick, and advanced tissue regeneration are growing at double-digit rates with higher gross margins than the corporate average.
  • Following the Waters separation, Becton Dickinson has executed significant capital returns including $2.3 billion in share repurchases year-to-date in fiscal 2026.
  • The company retired $2.1 billion of debt while maintaining a healthy net leverage ratio of approximately 2.9x, strengthening its balance sheet.
Risk Factors
  • An active product recall highlights ongoing execution risks that could impact reputation or sales across the broader portfolio.
  • The company faces significant pressure if weakness in the Chinese market persists, which could affect global revenue streams.
  • There is a risk that FDA actions regarding infection prevention products could expand or take longer to resolve than anticipated.
Full Analysis
Becton Dickinson (BDX) recently released positive nine-month clinical data from the AGILITY trial for its Revello Vascular Covered Stent, which successfully met its primary endpoint in treating iliac artery disease. This development adds to a busy October for the company, characterized by a new U.S. government manufacturing partnership and a leadership change within its Surgery unit. Despite facing an active product recall that highlights ongoing execution risks across its portfolio, BDX's stock has demonstrated significant momentum, gaining 20.28% over the past 90 days. The company is executing a strategic shift toward a focused medtech portfolio where over 90% of revenue comes from businesses growing in the mid-to-high single digits, with key platforms like biologic drug delivery and Advanced Patient Monitoring growing at double-digit rates. Following the separation of its Waters division, Becton Dickinson has adopted a shareholder-friendly capital allocation strategy, including approximately $2.3 billion in share repurchases year-to-date in fiscal 2026 and the retirement of $2.1 billion in debt while maintaining net leverage around 2.9x. Analysts currently view the stock as undervalued with a fair value estimate of $195.67 against a recent closing price of $182.75, suggesting potential upside despite risks related to persistent weakness in China and potential regulatory actions on infection prevention products.